THE EVALUATION OF SAFETY AND ADVERSE EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION IN PATIENTS WITH MUSCULAR DYSTONIA
Abstract
About the Authors
T. N. CharnukhaBelarus
S. A. Likhachev
Belarus
V. U. Hleb
Belarus
G. V. Zabrodzets
Belarus
References
1. Brin M.F., Hallett M., Jankovic J. Scientific and therapeutic aspects of botulinum toxic. New York, 2002.
2. Albanese A., Asmus F., Bhatia K.P. et al. // J. Eur. Neurol. 2011. № 18. P. 5-18.
3. Klein C.,Ozelius L. // Curr. Opin. Neurol. 2002. № 15. P. 491-497.
4. Tyvaert L., Houdayer E., Devanne H. et al. // Neurophysiol. Clin. 2006. № 36. P. 135-143.
5. Lefaucheur J.P., André-Obadia N., Antal A. // Clin. Neurophysiol. 2014. № 22. P. 293-296.
6. Dressier D. Botulinum toxin therapy.Stuttgart, 2000.
7. Rossi S., Hallett M., Rossini P.M. et al. // ClinNeurophysiol. 2009. № 120. P. 2008-2039.
Review
For citations:
Charnukha T.N., Likhachev S.A., Hleb V.U., Zabrodzets G.V. THE EVALUATION OF SAFETY AND ADVERSE EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION IN PATIENTS WITH MUSCULAR DYSTONIA. Doklady BGUIR. 2016;(7):371-373. (In Russ.)